Beyondspring Inc (BYSI) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Beyondspring Inc   (NASDAQ: BYSI)


Beyondspring Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Beyondspring Inc's ROI in the second quarter of 2026?
Beyondspring Inc recorded a cumulative net loss of $-23 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -307.59%.

Within the Healthcare sector 695 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3900 to 3993.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM -57.62 % 1131.77 % - - 2377.09 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions -10 10 12 17 32
Return On Investment (TTM) - -122.5 % -55.75 % -39.09 % -72.17 %
BYSI's Overall Ranking # 3993 # 3900 # 3350 # 3333 # 3392
Seq. Investment Change TTM -58.28 % -29.38 % -24.29 % 89.99 % 1112.71 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -23 -22 -14 -13 -13

BYSI Company Profile >> Back to BYSI Roi Comparisons >> See Annual BYSI Return On Investment



Return On Investment BYSI's Ranking
Within: No.
Industry # 321
Sector # 696
Overall # 3993

Return On Investment Statistics
High Average Low
-38.85 %
-288.17 %
-1036.11 %
(Sep 30 2025)   (Dec 31 2019)



  News about Beyondspring Inc Return on Investment ROI

Augmenting Metastatic NSCLC Treatment New Hope with a Triple Immunotherapy Approach Post-Checkpoint Inhibition...

November 11, 2024

The treatment landscape for metastatic non-small cell lung cancer (NSCLC) has significantly evolved with the advent of immune checkpoint inhibitors (ICIs). Despite initial efficacy, resistance often follows treatment, necessitating novel therapeutic approaches. BeyondSpring s recent study presented at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting investigates a promising combination therapy of pembrolizumab with plinabulin and docetaxel in patients who have previously progressed on PD-1/PD-L1 inhibitors. This article provides a detailed analysis of the study’s findings, highlights its implications, and discusses future directions in the management of advanced NSCLC. NSCLC accounts for the majority of lung cancer cases globally, with a notable proportion expressing PD-1/PD-L1 markers. Immune checkpoint inhibitors (ICIs) such as pembrolizumab have revolutionized the treatment of advanced NSCLC, offering durable responses and improved survival. However, the development of resistance to ICIs remains a critical challenge. The study by BeyondSpring focuses on a triple immunotherapy (IO) regimen aimed at overcoming this hurdle by combining pembrolizumab, a PD-1 inhibitor, with plinabulin, a selective immunomodulatory agent, and docetaxel, a cytotoxic chemotherapeutic agent.

Advancing Oncology BeyondSprings Promising Phase 3 Findings for Plinabulin in EGFR Wild-Type NSCLC

September 10, 2024

BeyondSpring Inc. recently delivered a significant oral presentation at the ISLAC 2024 World Conference on Lung Cancer, highlighting the final Phase 3 data for its lead anti-cancer asset, Plinabulin, in the context of second-line (2L) and third-line (3L) non-small cell lung cancer (NSCLC) among EGFR wild-type patients. Alongside the presentation, critical findings were concurrently published in The Lancet Respiratory Medicine , underlining the potential of Plinabulin as an effective therapeutic option in a challenging treatment landscape.Lung cancer remains the leading cause of cancer-related mortality globally, with NSCLC accounting for the majority of cases. Despite advances in treatment, there is a pressing need for novel therapies that offer improved outcomes for patients, particularly those who have progressed following standard platinum-based chemotherapy. BeyondSpring’s innovative approach aims to address this unmet need through Plinabulin, which has demonstrated promising efficacy.





Financial Statements
Beyondspring Inc's II. Quarter Investments $ -10 Millions BYSI's Balance sheet
Beyondspring Inc's II. Quarter Income $ -6 Millions Quarterly BYSI's Income Statement
BYSI's Income by Division See BYSI's Income by Division


BYSI Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020
Total Investments in Millions 16 45 23 62 104
Y / Y Investment Growth -64.94 % 96.91 % -62.81 % -40.56 % 213.47 %
Net Income in Millions -14 -17 -36 -68 -64
Y / Y Net Income Growth - - - - -
Annual Return On Investment -89.8 % -36.96 % -158.19 % -110.62 % -61.52 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
BYSI's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for BYSI's Competitors
Subscribers only: Roi for Beyondspring Inc's Suppliers
Subscribers only: Return On Investment for BYSI's Customers

Other Ratios
BYSI's Roa BYSI's Inventory Turnover Ratio BYSI's Growth Rates BYSI's Dividend Statistics
BYSI's Profitability Ratios BYSI's Asset Turnover Ratio BYSI's Dividend Growth
BYSI's Roe BYSI's Valuation Ratios BYSI's Financial Strength Ratios BYSI's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-26T07:31:36+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.